Ezlopitant is a selective, non-peptidic neurokinin-1 (NK-1) receptor antagonist that was primarily investigated for its potential in managing conditions such as chemotherapy-induced emesis and irritable… Read more
Ezlopitant is a selective, non-peptidic neurokinin-1 (NK-1) receptor antagonist that was primarily investigated for its potential in managing conditions such as chemotherapy-induced emesis and irritable bowel syndrome. Although its clinical development was ultimately discontinued, the compound remains a subject of ongoing pharmacological and neuroscience research, particularly regarding its effects on appetitive behavior and reward pathways. This category provides access to high-quality reference standards essential for analytical testing and development. Pharmaceutical laboratories utilize these materials, which include the parent compound, its various enantiomers, and identified impurities such as N-nitroso derivatives, for rigorous impurity profiling and method validation. These research-grade compounds support the precise characterization of the active pharmaceutical ingredient and its degradation products, ensuring consistency and accuracy in experimental protocols and developmental studies where this NK-1 receptor antagonist is employed.